Global Oral Transmucosal Drugs Market Growth, Size, Trends Analysis - By Product Type, By Route of Administration, By Indication, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Oral Transmucosal Drugs Market Introduction and Overview

According to SPER market research, 'Global Oral Transmucosal Drugs Market Size- By Product Type, By Route of Administration, By Indication, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Oral Transmucosal Drugs Market is predicted to reach 71.75 billion by 2034 with a CAGR of 6.94%.

Oral transmucosal drugs are medicines that are absorbed through the mouth's mucous membranes, providing quick relief while bypassing first metabolism in the liver and gastrointestinal system. These medications are frequently used for disorders that require immediate relief, such as pain management, as well as for people who have difficulty swallowing pills. Tablets, films, liquid formulations, sprays, and other similar forms are the most common oral transmucosal medications.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product Type, By Route of Administration, By Indication, By Distribution Channel

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Aquestive Therapeutics, Inc, C.L.Pharm Co., Ltd, Cure Pharmaceutical, IntelGenx Technologies Corp, Jazz Pharmaceuticals, plc, NAL Pharma, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, ZIM Laboratories Limited.

Global Oral Transmucosal Drugs Market Segmentation:

By Product Type: Based on the Product Type, Global Oral Transmucosal Drugs Market is segmented as; Tablet, Film, Liquid & Spray.

By Route of Administration: Based on the Route of Administration, Global Oral Transmucosal Drugs Market is segmented as; Sublingual mucosa, Buccal mucosa, Other routes of administration.

By Indication: Based on the Indication, Global Oral Transmucosal Drugs Market is segmented as; Opioid Dependence, Nausea & Vomiting, Erectile Dysfunction, Neurological Disorders.

By Distribution Channel: Based on the Distribution Channel, Global Oral Transmucosal Drugs Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: PHAR2513

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Oral Transmucosal Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Oral Transmucosal Drugs Market

7. Global Oral Transmucosal Drugs Market, By Product Type (USD Million) 2021-2034

7.1. Tablets
7.2. Films
7.3. Liquid & spray
7.4. Other product types

8. Global Oral Transmucosal Drugs Market, By Route of Administration (USD Million) 2021-2034

8.1. Sublingual mucosa
8.2. Buccal mucosa
8.3. Other routes of administration

9. Global Oral Transmucosal Drugs Market, By Indication (USD Million) 2021-2034

9.1. Opioid dependence
9.2. Nausea and vomiting
9.3. Erectile dysfunction
9.4. Neurological disorders
9.5. Other indications

10. Global Oral Transmucosal Drugs Market, By Distribution Channel (USD Million) 2021-2034

10.1. Hospital pharmacies
10.2. Retail pharmacies
10.3. Online pharmacies

11. Global Oral Transmucosal Drugs Market, (USD Million) 2021-2034

11.1. Global Oral Transmucosal Drugs Market Size and Market Share

12. Global Oral Transmucosal Drugs Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6.Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Aquestive Therapeutics, Inc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. C.L.Pharm Co., Ltd
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Cure Pharmaceutical
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. IntelGenx Technologies Corp
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Jazz Pharmaceuticals, plc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. NAL Pharma
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Novartis AG
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Pfizer Inc
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Teva Pharmaceutical Industries Limited
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. ZIM Laboratories Limited
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others